Floris L van Delft
Overview
Explore the profile of Floris L van Delft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shajan I, Rochet L, Tracey S, Benazza R, Jackowska B, Hernandez-Alba O, et al.
Bioconjug Chem
. 2024 Sep;
PMID: 39284580
Redirecting T cells to tumor cells by bispecific antibodies is an effective approach to treat cancer, and T cell-dependent bispecific antibodies (TDBAs) are an emerging class of potent immunotherapeutic agents....
2.
Shajan I, Rochet L, Tracey S, Jackowska B, Benazza R, Hernandez-Alba O, et al.
Bioconjug Chem
. 2023 Nov;
34(12):2215-2220.
PMID: 37962868
Bispecific antibodies as T cell engagers designed to display binding capabilities to both tumor-associated antigens and antigens on T cells are considered promising agents in the fight against cancer. Even...
3.
Damen J, Escorihuela J, Zuilhof H, van Delft F, Albada B
Chemistry
. 2023 Mar;
29(39):e202300231.
PMID: 36942680
Reaction rates of strained cycloalkynes and cycloalkenes with 1,2-quinone were quantified by stopped flow UV-Vis spectroscopy and computational analysis. We found that the strained alkyne BCN-OH 3 (k 1824 M ...
4.
de Bever L, Popal S, van Schaik J, Rubahamya B, van Delft F, Thurber G, et al.
Bioconjug Chem
. 2023 Mar;
34(3):538-548.
PMID: 36857521
GlycoConnect technology can be readily adapted to provide different drug-to-antibody ratios (DARs) and is currently also evaluated in various clinical programs, including ADCT-601 (DAR2), MRG004a (DAR4), and XMT-1660 (DAR6). While...
5.
Wijdeven M, van Geel R, Hoogenboom J, Verkade J, Janssen B, Hurkmans I, et al.
MAbs
. 2022 May;
14(1):2078466.
PMID: 35634725
Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how...
6.
Khera E, Dong S, Huang H, de Bever L, van Delft F, Thurber G
Mol Cancer Ther
. 2021 Dec;
21(2):310-321.
PMID: 34911819
After several notable clinical failures in early generations, antibody-drug conjugates (ADC) have made significant gains with seven new FDA approvals within the last 3 years. These successes have been driven...
7.
Bruins J, Damen J, Wijdeven M, Lelieveldt L, van Delft F, Albada B
Bioconjug Chem
. 2021 Sep;
32(10):2167-2172.
PMID: 34519477
The availability of tools to generate homogeneous and stable antibody conjugates without recombinant DNA technology is a valuable asset in fields spanning from diagnostics to imaging and therapeutics. We present...
8.
Verkade J, Wijdeven M, van Geel R, Janssen B, van Berkel S, van Delft F
Antibodies (Basel)
. 2019 Sep;
7(3).
PMID: 31544884
The conflict of interest section of the published paper [1] has been updated as follows[...].
9.
Verkade J, Wijdeven M, van Geel R, Janssen B, van Berkel S, van Delft F
Antibodies (Basel)
. 2019 Sep;
7(1).
PMID: 31544864
Despite tremendous efforts in the field of targeted cancer therapy with antibody-drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of...
10.
Bruins J, van de Wouw C, Wagner K, Bartels L, Albada B, van Delft F
ACS Omega
. 2019 Aug;
4(7):11801-11807.
PMID: 31460288
Knob-in-hole antibodies can be utilized to introduce a single tag for chemo-enzymatic functionalization. By either introducing a single C-terminal sortase tag (sortase-tag expressed protein ligation) or tyrosine tag (GY), mono-functionalization...